APO-OXAZEPAM 30 MG — DIN 00402737
OXAZEPAM : 30 MG · APOTEX INC · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is APO-OXAZEPAM?
APO-OXAZEPAM 30 MG contains OXAZEPAM : 30 MG. It is listed in the Health Canada Drug Product Database under DIN 00402737, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 31-Dec-1979. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-OXAZEPAM used for?
Short-term symptomatic relief of excessive anxiety and tension in anxiety neurosis; relief of symptoms of acute alcoholic withdrawal (agitation and impending delirium tremens).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Oxazepam in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
10 holders have a Canadian DIN containing Oxazepam, across 31 DINs, of which 9 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| APOTEX INC | 3 | 3 | APO-OXAZEPAM | Sourceable in Canada |
| LABORATOIRE RIVA INC. | 3 | 3 | RIVA-OXAZEPAM | Sourceable in Canada |
| PRO DOC LIMITEE | 3 | 3 | PRO-OXAZEPAM | Sourceable in Canada |
| BIOMED PHARMA | 6 | 0 | BIO-OXAZEPAM, OXPAM | No marketed DIN |
| LABORATOIRES CONFAB INC | 3 | 0 | OXAZEPAM 10MG TABLETS, OXAZEPAM 15MG TABLETS, OXAZEPAM 30MG TABLETS | No marketed DIN |
| NOVOPHARM LIMITED | 3 | 0 | NOVOXAPAM TAB 10MG, NOVOXAPAM TAB 15MG, NOVOXAPAM TAB 30MG | No marketed DIN |
| PHARMASCIENCE INC | 3 | 0 | PMS-OXAZEPAM TAB 10MG, PMS-OXAZEPAM TAB 15MG, PMS-OXAZEPAM TAB 30MG | No marketed DIN |
| WYETH-AYERST CANADA INC. | 3 | 0 | SERAX TABLETS 10MG, SERAX TABLETS 15MG, SERAX TABLETS 30MG | No marketed DIN |
| D.C. LABS LIMITED | 2 | 0 | OXAZEPAM TABLETS 15MG, OXAZEPAM TABLETS 30MG | No marketed DIN |
| WYETH LTD. | 2 | 0 | SERAX TAB 15MG, SERAX TAB 30MG | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 30 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Bottles of 100, 500, and 1000 tablets; unit dose packages of 100 (10x10) tablets. |
| Storage | Not explicitly specified in the provided text (Section 11 is listed in TOC but content is missing), though standard pharmaceutical storage is implied. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Oxazepam |
|---|---|
| ATC code | N05BA04 |
| AHFS class | 28:24.08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00402737 |
|---|---|
| DIN (unpadded, as printed on some documents) | 402737 |
| Brand name | APO-OXAZEPAM |
| Generic / active ingredient | OXAZEPAM : 30 MG |
| Market authorization holder | APOTEX INC |
| Health Canada schedule | TARGETED SUBSTANCES (CDSA IV) |
| ATC code | N05BA04 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N05BA |
| Current status | MARKETED |
| Status date | 31-Dec-1979 |
| Original market date | 1979-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Adults: 30-120 mg daily in divided doses. Elderly/Debilitated: 5 mg once or twice daily. Use lowest effective dose for shortest duration. Taper gradually to discontinue.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to benzodiazepines, infants, history of glaucoma, and myasthenia gravis.
Warnings and precautions
Serious risks of addiction, abuse, misuse, and life-threatening withdrawal. Concomitant use with opioids may cause respiratory depression and death. Risk of falls and fractures.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
9 of 31 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-OXAZEPAM | 15 MG | TABLET | APOTEX INC | MARKETED | 00402745 |
| APO-OXAZEPAM | 10 MG | TABLET | APOTEX INC | MARKETED | 00402680 |
| PRO-OXAZEPAM | 30 MG | TABLET | PRO DOC LIMITEE | MARKETED | 00497770 |
| PRO-OXAZEPAM | 10 MG | TABLET | PRO DOC LIMITEE | MARKETED | 00497754 |
| PRO-OXAZEPAM | 15 MG | TABLET | PRO DOC LIMITEE | MARKETED | 00497762 |
| RIVA-OXAZEPAM | 15 MG | TABLET | LABORATOIRE RIVA INC. | MARKETED | 00568406 |
| RIVA-OXAZEPAM | 30 MG | TABLET | LABORATOIRE RIVA INC. | MARKETED | 00568414 |
| RIVA-OXAZEPAM | 10 MG | TABLET | LABORATOIRE RIVA INC. | MARKETED | 00568392 |
| BIO-OXAZEPAM | 10 MG | TABLET | BIOMED PHARMA | CANCELLED POST MARKET | 02247177 |
| BIO-OXAZEPAM | 15 MG | TABLET | BIOMED PHARMA | CANCELLED POST MARKET | 02247178 |
2 · Same class — other molecules in ATC N05BA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Lorazepam | APO-LORAZEPAM · ATIVAN · ATIVAN INJ 4MG/ML · ATIVAN INJECTION LIQ 4MG/ML · +21 more | 53 | 17 | Yes |
| Alprazolam | ALPRAZOLAM · ALPRAZOLAM TABLETS 0.25 · ALPRAZOLAM TABLETS 0.5MG · APO-ALPRAZ · +17 more | 50 | 13 | Yes |
| Oxazepam | APO-OXAZEPAM · BIO-OXAZEPAM · NOVOXAPAM TAB 10MG · NOVOXAPAM TAB 15MG · +17 more | 31 | 9 | Yes |
| Diazepam | BIO-DIAZEPAM · DIASTAT · DIAZEMULS · DIAZEPAM · +23 more | 38 | 8 | Yes |
| Bromazepam | ALTI-BROMAZEPAM 1.5MG TABLETS · ALTI-BROMAZEPAM 3MG TABLETS · ALTI-BROMAZEPAM 6MG TABLETS · APO-BROMAZEPAM · +14 more | 24 | 4 | Yes |
| Clorazepate Potassium | CLORAZEPATE · NOVO-CLOPATE CAP 15MG · NOVO-CLOPATE CAP 3.75MG · NOVO-CLOPATE CAP 7.5MG · +3 more | 9 | 3 | Yes |
| Clobazam | APO-CLOBAZAM · CLOBAZAM-10 · DOM-CLOBAZAM · FRISIUM TAB 10MG · +6 more | 10 | 2 | Yes |
| Chlordiazepoxide | CHLORDIAZEPOXIDE · CHLORDIAZEPOXIDE CAP 10MG · CHLORDIAZEPOXIDE CAP 5MG · CHLORDIAZEPOXYDE 25 CAP · +10 more | 16 | 1 | Yes |
| Ketazolam | LOFTRAN CAP 30MG | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N05B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N05BE | Buspirone | 25 | 7 |
| N05BB | Hydroxyzine | 29 | 5 |
| N05BC | Meprobamate | 7 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is APO-OXAZEPAM called?
The same molecule, Oxazepam, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Sobril | Latin | Norway |
| Delipam | Latin | Norway |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
What is Oxazepam called in other languages?
Buyers, prescribers and procurement teams outside Canada often search for the ingredient in their own script. These are phonetic renderings of the ingredient name Oxazepam, published to help those searches reach this page.
| Language | Oxazepam |
|---|---|
| Arabic العربية | أوكسازيبام |
| Chinese (Simplified) 简体中文 | 奥沙西泮 |
| Russian Русский | Оксазепам |
| Portuguese Português | Oxazepam |
| German Deutsch | Oxazepam |
| Japanese 日本語 | オキサゼパム |
These are transliterations of the ingredient name, generated automatically and published only where two independent checks agreed. They are not registered local trade names and carry no marketing authorisation in any market. Always confirm a product against its local registration before ordering.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.